ArticleApplied microbiology and biotechnology2026
N-Glycosylation of Band 3 is essential for the binding of Ganoderma lucidum immunomodulatory protein rLZ-8.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Fungal immunomodulatory proteins (FIPs) are considered potential therapeutic candidates due to their immunomodulatory and anti-cancer activities. Meanwhile, they are capable of agglutinating mammalian red blood cells in a manner similar to lectins. Herein, GST-tagged rLZ-8, the first identified FIP in Ganoderma lucidum, was employed as bait to pull down its target proteins from mouse red blood cells. An important membrane protein, Band 3, was found to interact with rLZ-8. The result was confirmed by detecting the interactions of rLZ-8 with mBand 3 and hBand 3 heterologously expressed in HEK293 cells. Moreover, the interaction specifically required the sole N-glycosylation of Band 3 at its extracellular loop (between the seventh and eighth transmembrane helices), as evidenced by diminished binding both to the wild-type hBand 3 pretreated with the N-glycan trimming enzyme PNGaseF in vitro or with the mannosidase inhibitor (N-glycosylation processing enzyme) kifunensine (KIF) in vivo and to the N642D-hBand 3 (N660D-mBand 3) mutant. Consistently, both the binding of LZ-8 to Band 3 and its hemagglutinating property were inhibited by the highly glycosylated protein bovine mucin. These results suggest that the hemagglutinating ability of LZ-8 may be attributed to its binding to the N-glycosylated proteins, including Band 3, on the erythrocyte surface. Furthermore, supporting the clinical safety profile of FIPs, stopped-flow analysis performed on human red blood cell ghosts demonstrated that the Cl⁻/HCO₃⁻ exchange activity of Band 3 remained unaltered upon binding to LZ-8. KEY POINTS: This study first reported the interaction between Band 3 and FIPs. The sole N-glycosylation of Band 3 is critical for the binding of FIPs. The addition of LZ-8 does not alter the Cl⁻/HCO₃⁻ exchange activity of human red blood cell ghosts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.